Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"
Hbuitendijk (talk | contribs) |
Hbuitendijk (talk | contribs) |
||
| Line 30: | Line 30: | ||
<!-- The name of the committee that is proposed to have responsibility for developing and maintaining the resources. --> | <!-- The name of the committee that is proposed to have responsibility for developing and maintaining the resources. --> | ||
| − | [[Orders & Observations | + | [[Orders & Observations]] |
==Committee Approval Date:== | ==Committee Approval Date:== | ||
| Line 38: | Line 38: | ||
<!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | <!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | ||
| − | * | + | * [[Patient Care]] |
| − | * Pharmacy | + | * [[Pharmacy]] |
==FHIR Resource Development Project Insight ID== | ==FHIR Resource Development Project Insight ID== | ||
Revision as of 17:56, 28 September 2017
This page documents a Pending FHIR Resource Proposal
Contents
- 1 BiologicallyDerivedProduct
- 1.1 Owning committee name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Resource Relationships
- 1.11 Timelines
- 1.12 gForge Users
- 1.13 When Resource Proposal Is Complete
- 1.14 FMG Notes
BiologicallyDerivedProduct
Owning committee name
Committee Approval Date:
Please enter the date that the committee approved this Resource proposal
Contributing or Reviewing Work Groups
FHIR Resource Development Project Insight ID
1128 Patient Care FHIR resource review
Scope of coverage
A material substance originating from a biological entity intended to be transplanted or infused into another (possibly the same) biological entity.
Examples include:
- hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
- blood (whole, extracted cells, plasma, etc)
- organs
- tissues (porcine valves, skin, bovine cardiac tissue, etc.)
- manipulated cells (e.g. CAR T-cells)
RIM scope
No identified mappings to RIM 2.46 objects.
Resource appropriateness
Organs, tissues, and fluids obtained from one biological entity (person or animal) for the purpose of infusion, transplantation or grafting to another biological entity are neither Specimens ("used for diagnostic and environmental testing") nor Devices ("an instance or a type of a manufactured item") nor Medications (drug, ingredients, and packaging) nor Substances ("homogeneous material with a definite composition"). Furthermore, there is established a relationship between two entities, the donor and the recipient.
Expected implementations
Content sources
- Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct
- Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person
- Patient receives post-HCT infusion of donor t-cells
- Patient receives blood (BiologicallyDerivedProduct) transfusion
- Patient receives HLA-matched platelets (BiologicallyDerivedProduct)
- Patient receives heart transplant
- Patient undergoes cardiac surgery receiving pig heart valve
Resource Relationships
ProcedureRequest Patient Practitioner Substance
Timelines
gForge Users
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
